Subscribe to RSS
DOI: 10.1055/s-0036-1579692
Vision Disturbances in Multiple Sclerosis
Publication History
Publication Date:
26 April 2016 (online)
![](https://www.thieme-connect.de/media/sin/201602/lookinside/thumbnails/10-1055-s-0036-1579692_0072-1.jpg)
Abstract
Visual disturbances are frequently encountered in multiple sclerosis (MS), and include problems with how affected individuals see the world (afferent visual pathway symptoms) and how their eyes move together (efferent visual pathway disorders). Optic neuritis is the most common afferent visual pathway manifestation of MS, from which visual recovery is often incomplete. Visual field defects caused by lesions in the retrochiasmal or retrogeniculate regions of the afferent visual pathway also occur, albeit less frequently. Efferent visual pathway lesions causing ocular misalignment and nystagmus may lead to diplopia and oscillopsia, respectively. Vision loss has a major impact on perceptions regarding quality of life in MS. Therefore, it is important for clinicians to be able to identify and localize the underlying basis of visual disturbances to provide the best care possible for their patients.
-
References
- 1 Costello F. The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis. ISRN Neurol 2013; 2013: 134858
- 2 Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain 2015; 138 (Pt 1) 11-27
- 3 Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372 (9648) 1502-1517
- 4 Costello FE, Lee AG, Burton JM. Neuro-ophthalmic manifestations of multiple sclerosis. Available at: http://emedicine.medscape.com/article/1214270-overview . Accessed January 22, 2015
- 5 Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4 (5) 281-288
- 6 Costello F, Burton JM. An approach to optic neuritis: the initial presentation. Expert Rev Ophthalmol 2013; 8 (6) 539-551
- 7 Beck RW, Cleary PA, Anderson Jr MM , et al; The Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326 (9) 581-588
- 8 Beck RW. Optic neuritis. In: Miller NR, Newman NJ, , eds. Walsh & Hoyt's Clinical Neuro-Ophthalmology. Vol, 5. 5th ed. Baltimore, MD: Williams & Wilkins; 1999: 599-647
- 9 Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006; 67 (2) 258-262
- 10 Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW ; Optic Neuritis Study Group. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol 2010; 128 (3) 330-337
- 11 Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet 2002; 360 (9349) 1953-1962
- 12 Costello F. Inflammatory optic neuropathies. Continuum (Minneap Minn) 2014; 20 (4 Neuro-ophthalmology): 816-837 (Minneap Minn)
- 13 Shams PN, Plant GT. Optic neuritis: a review. Int MS J 2009; 16 (3) 82-89
- 14 Polman CH, Reingold SC, Banwell B , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (2) 292-302
- 15 Modvig S, Degn M, Horwitz H , et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS ONE 2013; 8 (10) e77163
- 16 Heussinger N, Kontopantelis E, Gburek-Augustat J , et al; for GRACE-MS (German-speaking Research Alliance for ChildrEn with Multiple Sclerosis). Oligoclonal bands predict multiple sclerosis in children with optic neuritis. Ann Neurol 2015; 77 (6) 1076-1082
- 17 Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354 (12) 1273-1280
- 18 van der Walt A, Kolbe S, Mitchell P , et al. Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis. PLoS ONE 2015; 10 (5) e0121084
- 19 Sriram P, Wang C, Yiannikas C , et al. Relationship between optical coherence tomography and electrophysiology of the visual pathway in non-optic neuritis eyes of multiple sclerosis patients. PLoS ONE 2014; 9 (8) e102546
- 20 Syc SB, Saidha S, Newsome SD , et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012; 135 (Pt 2) 521-533
- 21 Costello F, Pan YI, Yeh EA, Hodge W, Burton JM, Kardon R. The temporal evolution of structural and functional measures after acute optic neuritis. J Neurol Neurosurg Psychiatry 2015; 86 (12) 1369-1373
- 22 Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E , et al. Dynamics of retinal injury after acute optic neuritis. Ann Neurol 2015; 77 (3) 517-528
- 23 Petzold A, de Boer JF, Schippling S , et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010; 9 (9) 921-932
- 24 Fisher JB, Jacobs DA, Markowitz CE , et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113 (2) 324-332
- 25 Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N ; Optic Neuritis Study Group. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007; 69 (6) 508-514
- 26 Raz N, Dotan S, Benoliel T, Chokron S, Ben-Hur T, Levin N. Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 2011; 76 (24) 2103-2111
- 27 The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65 (6) 727-732
- 28 Martinelli V, Rocca MA, Annovazzi P , et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009; 73 (22) 1842-1848
- 29 Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009; 8 (3) CD006921
- 30 Raz N, Chokron S, Ben-Hur T, Levin N. Temporal reorganization to overcome monocular demyelination. Neurology 2013; 81 (8) 702-709
- 31 Pineles SL, Birch EE, Talman LS , et al. One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol 2011; 152 (1) 133-140
- 32 Saidha S, Sotirchos ES, Ibrahim MA , et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11 (11) 963-972
- 33 Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012; 135 (Pt 6) 1786-1793
- 34 Saidha S, Syc SB, Ibrahim MA , et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011; 134 (Pt 2) 518-533
- 35 Kaya D, Kaya M, Özakbaş S, İdiman E. Uveitis associated with multiple sclerosis: complications and visual prognosis. Int J Ophthalmol 2014; 7 (6) 1010-1013
- 36 Gordon LK, Goldstein DA. Gender and uveitis in patients with multiple sclerosis. J Ophthalmol 2014; 2014: 565262
- 37 McClelland C, Galetta S. Eye symptoms, signs, and therapy in multiple sclerosis. In: Rae-Grant A, Fox R, Bethoux F, , eds. Multiple Sclerosis and Related Disorders: Diagnosis, Medical Management, and Rehabilitation. New York: Demos Medical Publishing; 2013: 179-86
- 38 Walsh RD, McClelland CM, Galetta SL. The neuro-ophthalmology of multiple sclerosis. Future Neurol 2012; 7 (6) 679-700
- 39 Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012; 78 (9) 672-680
- 40 Bermel RA, Villoslada P. Retrograde trans-synaptic degeneration in MS: a missing link?. Neurology 2014; 82 (24) 2152-2153
- 41 Sørensen PS, Bertolotto A, Edan G , et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18 (2) 143-152
- 42 Prasad S, Galetta SL. Eye movement abnormalities in multiple sclerosis. Neurol Clin 2010; 28 (3) 641-655
- 43 Frohman TC, Galetta S, Fox R , et al. Pearls & Oy-sters: the medial longitudinal fasciculus in ocular motor physiology. Neurology 2008; 70 (17) e57-e67
- 44 Wong AM. Understanding skew deviation and a new clinical test to differentiate it from trochlear nerve palsy. J AAPOS 2010; 14 (1) 61-67
- 45 Straube A, Bronstein A, Straumann D. Nystagmus and oscillopsia. In: Gilhus NE, Barnes MP, Brain M, , eds. European Handbook of Neurological Management. Vol. 1. 2nd ed. Oxford: Blackwell Publishing Ltd; 2011: 484-492